替考拉宁与万古霉素治疗与外科手术相关的复杂性皮肤及皮肤结构感染的比较。
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.
作者信息
Wilson Samuel E, O'Riordan William, Hopkins Alan, Friedland H David, Barriere Steven L, Kitt Michael M
机构信息
Department of Surgery, University of California, Irvine School of Medicine, Orange, CA, USA.
出版信息
Am J Surg. 2009 Jun;197(6):791-6. doi: 10.1016/j.amjsurg.2008.05.012. Epub 2008 Dec 18.
BACKGROUND
We compared telavancin with vancomycin for the treatment of complicated skin and skin-structure infections (cSSSI) caused by Gram-positive bacteria.
METHODS
This was a retrospective analysis of clinical and microbiologic efficacy assessed at test-of-cure (7 to 14 days after completing therapy) in 194 patients from 2 randomized, double-blind clinical trials comparing telavancin (10 mg/kg intravenous [IV] every 24 hours; n = 101) with vancomycin (1 g IV every 12 hours; n = 93) for the treatment of cSSSI.
RESULTS
Baseline characteristics were similar for both treatment groups. Clinical cure and microbiologic eradication rates demonstrated consistent trends favoring telavancin over vancomycin; however, the differences were not statistically significant. The incidence of adverse events was mostly similar between groups.
CONCLUSIONS
The efficacy of telavancin was at least equivalent to that of vancomycin for the treatment of cSSSI. These data suggest that telavancin may be a useful alternative for treatment of cSSSI caused by S. aureus, particularly MRSA.
背景
我们比较了替考拉宁与万古霉素治疗革兰氏阳性菌引起的复杂性皮肤及皮肤结构感染（cSSSI）的效果。
方法
这是一项回顾性分析，对来自两项随机双盲临床试验的194例患者在治疗结束后7至14天的临床和微生物学疗效进行评估，这两项试验比较了替考拉宁（每24小时静脉注射10mg/kg；n = 101）与万古霉素（每12小时静脉注射1g；n = 93）治疗cSSSI的效果。
结果
两个治疗组的基线特征相似。临床治愈率和微生物清除率显示出一致的趋势，即替考拉宁优于万古霉素；然而，差异无统计学意义。两组间不良事件的发生率大多相似。
结论
替考拉宁治疗cSSSI的疗效至少与万古霉素相当。这些数据表明，替考拉宁可能是治疗由金黄色葡萄球菌引起的cSSSI的有用替代药物，尤其是耐甲氧西林金黄色葡萄球菌（MRSA）。
Zotero 插件